From
Live Event Content
Reunión de la Medicina de Emergencia - Controversias en el manejo del asma grave en urgencias
With Dr. Natalia Paniagua & Dr. Viviana Pavlich & Dr. Javier Benito · hosted by Dr. Javier González del Rey
Chapter 1 of 6 · Fundamentals
Severity definitions
Defining severe asthma and status asmaticus: clinical criteria and terminology
Expert statements on this page
No expert statements were drawn from this page.
Host summaries · secondary, not cited in answers
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Video
Mental Health and Gun Safety in Pediatrics - Catherine Neyer - APP Conference 2026
48 min · Published May 2026
Video
Overview of the Surgical Management of Acute and Chronic Pancreatitis in Children with Dr. Juan Gurria
66 min · Published Apr 2026
Video
Clinical & Research Update: Pediatric Liver Tumors - A Case-Based Discussion with Drs. Katherine Somers & Alex Bondoc
69 min · Published Apr 2026
Video
Beyond ChatGPT_ AI Tools You’re Not Using (But Should) - Vail, CO
Dr. Todd Ponsky · 97 min · Published Jan 2026
Video
Beyond ChatGPT: AI Tools You’re Not Using (But Should)
Dr. Todd Ponsky · 109 min · Published Oct 2025
Video
2025 Pediatric Surgery Update Course - Updates in Lap Chole and Cholecystitis Management
18 min · Published Aug 2025
What the experts said
Multiple validated clinical pulmonary scores exist to categorize asthma severity (respiratory rate, retractions, auscultation), but the literature uses inconsistent definitions of 'status asmaticus,' making it difficult to compare studies.
When clinical scores disagree on severity, the higher (more severe) category should be used to guide treatment.
The term 'status asmaticus' should be reserved for patients who do not respond to initial treatment, rather than applied at presentation.
In severe asthma, MDI-spacer can also be effective if the patient can generate adequate inspiratory flow (approximately 40 liters per minute) to open the spacer valve.
Ipratropium has minor side effects compared to salbutamol, which supports its inclusion in first-line therapy for severe exacerbations.
In Paraguay, the national Ministry of Health does not supply ipratropium bromide, so it is not used in first-line asthma treatment despite evidence of benefit.
Continuous nebulization of salbutamol is operationally easier for nursing staff to implement than repeated bolus doses, which is one reason some centers adopt it as the default in severe cases.
Intravenous magnesium sulfate is a second-line bronchodilator with anti-inflammatory properties; it is typically given after initial bronchodilator therapy fails to produce improvement.
High-flow nasal cannula oxygen improves patient comfort and respiratory pattern in severe asthma, and may reduce the need for intubation.
Close bedside monitoring in the first hour after starting bronchodilator therapy is critical to detect early treatment failure and escalate therapy promptly.
A patient who shows initial improvement after two doses of bronchodilator but then deteriorates (increased work of breathing, falling heart rate) requires immediate escalation to IV magnesium or other second-line therapy.
A patient in true respiratory failure (altered mental status, poor perfusion, minimal air movement) belongs in the resuscitation bay with immediate preparation for intubation, not in a standard emergency department bed.
Adolescents with severe asthma are at higher risk for sudden deterioration and respiratory arrest; they require especially close monitoring.
In selected severe cases—marked suprasternal retractions, accessory muscle use, minimal air movement, oxygen saturation below 92 percent—intramuscular epinephrine is used as a rescue therapy to avoid intubation.
Intramuscular epinephrine in severe asthma is the same dose used for anaphylaxis; the rationale is that the child is in near-respiratory failure and standard bronchodilators have failed.
Aminophylline (theophylline) has a narrow therapeutic window and significant side effects (tachycardia, arrhythmia), which limits its use in modern practice.
Noninvasive ventilation (e.g., BiPAP) can forestall intubation in severe asthma if the team has expertise in airway management and the patient is not in frank respiratory failure.
High-flow nasal cannula oxygen has largely replaced noninvasive positive-pressure ventilation in many centers because it is easier to apply and better tolerated by children.
Ketamine is used as a sedative to facilitate noninvasive ventilation or to buy time before intubation in the sickest asthma patients; it has bronchodilator properties and preserves respiratory drive.
The lack of uniform definitions for 'severe' and 'critical' asthma has prevented high-quality comparative trials of second-line therapies; future research requires consensus severity criteria.
Metered-dose inhaler with spacer has been shown in multiple studies to be as effective as nebulization in mild-to-moderate asthma exacerbations.
Meta-analyses show that adding ipratropium bromide to salbutamol in the first-line treatment of severe asthma reduces hospital admission rates, particularly in children older than five years.
Inhaled beta-agonists (salbutamol/albuterol) remain the most potent bronchodilators available; no other agent has stronger evidence for acute asthma.
A child who arrives in the emergency department with severe asthma but is alert, cooperative, and able to use an MDI-spacer should receive that as first-line therapy; nebulization is reserved for those too distressed or fatigued to inhale effectively.
The choice of systemic corticosteroid (dexamethasone, methylprednisolone, prednisone) does not significantly affect outcomes in acute asthma; the route (oral vs. IV) should be guided by the patient's ability to tolerate oral medication.